UNSPSC 51172173: Fenpiprane hydrochloride

This classification denotes an anticholinergic agent with the molecular formula C20H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 684N1BF96B, chemically known as 3-piperidino-1,1-diphenylpropane hydrochloride but more generally known as fenpiprane hydrochloride, which bears US NIH Compound Identifier 197784. Most nations, for tariff and trade purposes, schedule fenpiprane hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, FENPIPRANE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Fenpiprane hydrochloride bears US NLM NCI C65667. SMILES: C1CCC(CC1)C(CCN2CCCCC2)C3CCCCC3.CL.

UNSPSC 51172173 Fenpiprane hydrochloride is a Commodity code representing a specific pharmaceutical active pharmaceutical ingredient. State and local governments do not appear to procure fenpiprane hydrochloride directly under this code based on recent solicitation activity. The three most recent state and local opportunities tagged to this code involve offender drug testing services (specimen collection, immunoassay screening, and confirmation testing), direct-to-manufacturer prescription programs through a state health and human services commission, and generic multi-source pharmaceuticals and OTC products through a multistate cooperative purchasing vehicle. None of these solicitations name fenpiprane hydrochloride as a line item or required product, suggesting a mismatch between the code assignment and the actual scope of work being procured.

The few opportunities on record span Texas (Collin County Community Supervision and Corrections Department and Texas Health and Human Services Commission) and a multistate cooperative purchasing alliance administered by Minnesota that includes Oregon participants. Collin County issued RFP 2026-327 for offender specimen collection and drug testing services with proposals due July 23, 2026, valued at approximately $600,000 over two years with three optional one-year renewals, requiring SAMHSA, Texas DPS, or CAP lab certification and screening and confirmation testing across two collection sites. The Texas HHS Commission posted an RFI on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP due March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be sourced through three authorized wholesalers, with contracts effective July 1, 2026. The code shows little activity genuinely aligned with fenpiprane hydrochloride procurement.